Metabolic Diseases World Summit 2005. 29 June-1 July 2005, San Francisco, CA, USA.
James
Stephen
S
Biovitrum AB, Stockholm, Lindhagensgatan 133, SE 11276, Sweden. stephen.james@biovitrum.com
D000682:Amyloid / Q000627:therapeutic use; D000818:Animals; D002772:Cholera Toxin / Q000037:antagonists & inhibitors; D018819:Dipeptidyl Peptidase 4 / Q000187:drug effects; D000077270:Exenatide; D006242:Haptoglobins; D006801:Humans; D007328:Insulin / Q000008:administration & dosage; D058228:Islet Amyloid Polypeptide; D008659:Metabolic Diseases / Q000188:drug therapy*; D009765:Obesity / Q000188:drug therapy; D010455:Peptides / Q000627:therapeutic use; D011498:Protein Precursors; D011988:Receptors, Thyroid Hormone / Q000187:drug effects; D014688:Venoms / Q000627:therapeutic use
D000682:Amyloid; D006242:Haptoglobins; D007328:Insulin; D058228:Islet Amyloid Polypeptide; D010455:Peptides; D011498:Protein Precursors; D011988:Receptors, Thyroid Hormone; D014688:Venoms; C408043:zonulin; D002772:Cholera Toxin; D000077270:Exenatide; C105254:pramlintide; D018819:Dipeptidyl Peptidase 4